A path forward towards accelerating cervical cancer eradication

Diana SM Buist, PhD, MPH
Senior Scientific Investigator, Kaiser Permanente Washington Health Research Institute
Professor, Kaiser Permanente Bernard J. Tyson School of Medicine

Affiliate Professor, University of Washington, School of Public Health, Departments of Epidemiology and Health Systems and Population Health

@dianabuist
Disclosures

• Funded by: NCI, AHRQ, PCORI and CDC
  • Co-I on Completed NCI trial: Home-Based Options to Make Cervical Cancer Screening Easy (HOME) trial NCT02005510 (R01 CA168598)
    Clinical outcomes in underscreened females
  • PI on NCI trial Self-Testing Options in the Era of Primary HPV Screening for Cervical Cancer Trial (STEP) - NCT04679675 (R01 CA240375)
    Screening uptake and completion by different outreach strategies stratified by screening history

• Employed by Kaiser Foundation Health Plan of Washington
Achieving the 90-70-90 targets by 2030 would result in over 62 million cervical cancer deaths averted by 2120.
Cancer Prevention through Vaccination with Long Sojourn time
US population of females aged 30-64

73,180,000
18,295,000
14,000
50%
Percent up-to-date with cervical cancer screening by insurance status in the US

Affordable Care Act Sept 2010

https://www.ncqa.org/hedis/measures/cervical-cancer-screening/
Randomized women

N=9,960

Randomized to in-home HPV screening arm

N=1,206

Return HPV kit

N=34

HPV16+ or HPV18+

N=102

Other hrHPV+ only

N=6

Unsat

hrHPV-

N=1,064

Pap or co-test

N=7,314

No Screening

N=1,440

Pap or co-test

N=8,172

No Screening

N=1,719

Randomized to usual care arm

N=9,891

Pap or co-test

N=7,314

No Screening

N=1,440

Pap or co-test

N=8,172

No Screening

N=1,719

JAMA Netw Open 2019
NCT02005510 (R01 CA168598)
Instructions for Your Cervical Cancer Screening Kit

Please do not use this kit if you are pregnant.

STEP 1
STEP 2
STEP 3
STEP 4
Understanding Patients’ Perspectives and Information Needs Following a Positive Home Human Papillomavirus Self-Sampling Kit Result

Jasmin A. Tiro, PhD,1 Andrea C. Betts, MPH,1,2 Kilian Kimbel, BA,3 Diana S.M. Buist, PhD,3 Constance Mao, MD,4 Hongyuan Gao, MS,3 Lisa Shulman, MSW,3 Colin Malone, MPH,5 Tara Beatty, MA,3 John Lin, BA,6 Chris Thayer, MD,7 Diana L. Miglioretti, PhD,3,8 and Rachel L. Winer, PhD3,5

Reactions of women underscreened for cervical cancer who received unsolicited human papillomavirus self-sampling kits

Colin Malone1, Jasmin A Tiro2, Diana SM Buist3, Tara Beatty3, John Lin1, Kilian Kimbel3, Hongyuan Gao3, Chris Thayer4, Diana L Miglioretti3,5 and Rachel L Winer1,3
Self-Testing options in the Era of Primary HPV screening for cervical cancer STEP Trial

31,619 females ages 30-64 due for cervical cancer screening recruited over 14 months

- **Screening Adherent**
  - N=13,735

- **Overdue**
  - N=8,388

- **Unknown**
  - N=9,496

**Usual Care**
- N=3,879

**Education**
- N=4,171

**Education+ Opt-In**
- N=4,171

**Education+ Direct Mail**
- N=1,514

**Usual Care**
- N=5,592

**Education**
- N=1,398

**Education+ Direct Mail**
- N=1,398

**Usual Care**
- N=2,124

**Education**
- N=3,686

**Education+ Opt-In**
- N=3,686

NCT04679675 (R01 CA240375) Clinical Trial: NCT04679675 (Buist/Winer)
Cervical Cancer Screening Postpandemic: Self-Sampling Opportunities to Accelerate the Elimination of Cervical Cancer

Taja Lozar, Rahul Nagvekar, Charles Rohrer, Racheal Shamiso Dube, Mandishora, Urska Ivanus, Megan Burke Fitzpatrick


Yuan-Po Tu, Jameel Iqbal, Timothy O’Leary

doi: https://doi.org/10.1101/2020.12.07.20245225

Now published in eLife doi: 10.7554/eLife.65726
Recommendations

• Learn from COVID
  ✓ Primary prevention & education: What has worked to address vaccine hesitancy, how have complex scientific concepts been relayed to the public
  ✓ Self-collection: increase validation and implementation evaluations
  ✓ Speed

• Multi-everything
  ✓ Multi-level, multi-site, multi-modalities (mixed methods), multi-lingual & multi-cultural

• Invest in training for researchers to communicate to various stakeholders

• Reform NIH funding paradigm
  ✓ Faster
  ✓ Innovative funding mechanisms (e.g., UG3-UH3; NIDDK PAR-20-160)
Thank you
@dianabuist